Peregrine Pharmaceut (PPHMP) 22.92 $PPHMP
Avid Bioservices to Participate in Cambridge Healthtech Institute's (CHI) 8th Annual The Bioprocessing Summit
GlobeNewswire - Tue Aug 09, 7:05AM CDT
Avid Bioservices, Inc., a wholly owned subsidiary of Peregrine Pharmaceuticals, Inc. (NASDAQ
PHM) (NASDAQPHMP), today announced that the company will have a significant presence at Cambridge Healthtech Institute's (CHI) 8 Annual The Bioprocessing Summit, being held August 15-19, 2016 in Boston, MA. The company's vice president of process sciences, Pete Gagnon, will make a presentation centered on the role of protein A in biomanufacturing and will serve as one of three expert participants for a panel discussion on technology advancements that can assist biological drug manufacturers in achieving optimal viral clearance during the performance of downstream purification processes.
PPHMP: 22.92 (+0.25), PPHM: 0.36 (unch)
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
GlobeNewswire - Thu Jun 02, 3:00PM CDT
Peregrine Pharmaceuticals, Inc. (NasdaqPHM) (NasdaqPHMP) today announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock"
.
PPHMP: 22.92 (+0.25), PPHM: 0.36 (unch)
Peregrine Pharmaceuticals Provides Corporate Update Highlighting Latest Developments for Contract Manufacturing and Drug Development Businesses
GlobeNewswire - Thu Jun 02, 7:05AM CDT
- Contract Manufacturing Revenue Hits All-Time High of $44 Million for Fiscal Year Ended April 2016; Fiscal Year 2017 Contract Manufacturing Revenue Projected Between $50-55 Million; Continued Growth Expected to Lead to Future Sustainable Profitability in 24 Months -
PPHMP: 22.92 (+0.25), PPHM: 0.36 (unch)
Avid Bioservices to Exhibit at the 2016 BIO International Convention
Marketwired - Tue May 31, 7:05AM CDT
Showcasing Expanded Contract Manufacturing Capabilities From Early Stage Development to Commercialization; Onsite Access to Leading Biopharmaceutical Manufacturing Experts
PPHMP: 22.92 (+0.25), PPHM: 0.36 (unch)
Avid Bioservices Appoints Pete Gagnon as Vice President of Process Sciences
Marketwired - Mon May 23, 7:05AM CDT
Leading Innovator in Field of Biologics Purification Brings Unique Manufacturing Experience to Broaden Avid's Capabilities, Including Biosimilar Expertise
PPHMP: 22.92 (+0.25), PPHM: 0.36 (unch)
Preclinical Data Presented at American Association for Cancer Research (AACR) Annual Meeting Demonstrate Enhanced Therapeutic Benefit of Combining a PS-Targeting Antibody With Anti-PD-1 Therapy in Models of Triple Negative Breast Cancer (TNBC)
GlobeNewswire - Wed Apr 20, 7:05AM CDT
- Statistically Significant Improvement in Overall Survival for Combination as Compared to Anti-PD-1 Therapy Alone in TNBC Models; Combination Also Protects Against Re-Challenge With TNBC Tumor Cells -
PPHMP: 22.92 (+0.25), PPHM: 0.36 (unch)
Peregrine Pharmaceuticals and National Comprehensive Cancer Network (NCCN) Form Clinical Collaboration to Evaluate Novel Cancer Treatment Combinations With Bavituximab
GlobeNewswire - Wed Jan 06, 7:05AM CST
Peregrine Pharmaceuticals, Inc. (NASDAQPHM) (NASDAQPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced a new research collaboration with the National Comprehensive Cancer Network(R) (NCCN(R)) to expand the company's ongoing clinical research and development of bavituximab for the treatment of a range of tumors. NCCN, a not-for-profit alliance of 26 of the world's leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Peregrine will fund multiple investigator-initiated clinical and correlative studies with bavituximab in multiple cancers at NCCN Member Institutions and their affiliate community hospitals through a $2 million research grant to NCCN's Oncology Research Program (ORP). NCCN will be responsible for oversight and monitoring of the clinical studies through the research grant.
PPHMP: 22.92 (+0.25), PPHM: 0.36 (unch)
Peregrine Pharmaceuticals Reports Financial Results for Second Quarter of Fiscal Year 2016 and Recent Developments
GlobeNewswire - Thu Dec 10, 3:05PM CST
--Peregrine and AstraZeneca Expand Immuno-Oncology Collaboration and Plan Phase II NSCLC Trial--
PPHMP: 22.92 (+0.25), PPHM: 0.36 (unch)
Peregrine Pharmaceuticals' board to pay USD0.65625 per preferred share dividend
M2 - Tue Dec 08, 3:44AM CST
The board of directors of Peregrine Pharmaceuticals (NasdaqPHMP) declared on Monday its quarterly dividend of USD0.65625 per share on its 10.50% Series E convertible preferred stock accruing from 1 October 2015 through 31 December 2015.
PPHMP: 22.92 (+0.25)
Peregrine to Report Financial Results for Second Quarter of Fiscal Year 2016 After Market Close on December 10, 2015
GlobeNewswire - Thu Dec 03, 3:05PM CST
Peregrine Pharmaceuticals, Inc. (NASDAQPHM) (NASDAQPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that it will report financial results for the second quarter of fiscal year 2016 ended October 31, 2015 on December 10, 2015 after market and will host a conference call and webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Peregrine's senior management will discuss financial results for the second quarter and review the recent progress of its clinical development programs.
PPHMP: 22.92 (+0.25), PPHM: 0.36 (unch)
Peregrine Pharmaceuticals to Participate in Two Upcoming Life Science Investor Conferences
GlobeNewswire - Mon Nov 23, 7:05AM CST
Peregrine Pharmaceuticals, Inc. (NASDAQPHM) (NASDAQPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that the company will participate in two upcoming life science investor conferences being held in New York during the month of December. Steven W. King, president and chief executive officer, will participate in a panel discussion focused on cancer immunotherapy at Piper Jaffray's 27 Annual Healthcare Conference. Additionally, the company will be one of only 16 life science companies attending Roth Capital Partners' Immuno-Oncology Corporate Access Day.
PPHMP: 22.92 (+0.25), PPHM: 0.36 (unch)
New Preclinical Data Presented at SITC Annual Meeting Highlight Bavituximab's Enhanced Anti-Tumor Activity When Combined With Checkpoint Inhibitors in Breast Cancer and Melanoma
GlobeNewswire - Mon Nov 09, 7:05AM CST
- Bavituximab in Combination with Anti-PD-1 in Breast Cancer Studies Showed a Statistically Significant Improvement in Overall Survival as Compared to Subjects Receiving Anti-PD-1 Therapy Alone -
PPHMP: 22.92 (+0.25), PPHM: 0.36 (unch)
AstraZeneca and Peregrine Pharmaceuticals Expand Ongoing Immuno-Oncology Collaboration to Include Phase II Lung Cancer Combination Clinical Trial
GlobeNewswire - Thu Oct 15, 7:05AM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQPHM) (NASDAQPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that it has expanded its ongoing cancer immunotherapy clinical collaboration with AstraZeneca to include a second, later-stage trial. The companies will now also evaluate the immunotherapy combination of Peregrine's phosphatidylserine (PS)-targeted immune-activator, bavituximab, and AstraZeneca's anti-PD-L1 immune checkpoint inhibitor, durvalumab (MEDI4736), in a global Phase II study in patients with previously treated squamous or non-squamous non-small cell lung cancer (NSCLC). The randomized Phase II trial will be conducted by Peregrine.
PPHMP: 22.92 (+0.25), PPHM: 0.36 (unch)
New Translational Data Highlights Bavituximab's Ability to Induce Signs of Immune Activation in Lung Cancer Tumor Samples With Negative PD-L1 Expression
GlobeNewswire - Tue Sep 08, 7:08AM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQPHM) (NASDAQPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced positive new data from a translational study of bavituximab, the company's investigational phosphatidylserine (PS)-signaling pathway inhibitor. Findings demonstrated the ability of bavituximab, alone or in combination with docetaxel, to induce signs of immune activation in non-small cell lung cancer (NSCLC) patient-derived tumor samples, particularly when there was negative PD-L1 expression in the tumor sample. These data further support the potential mechanistic synergies for bavituximab with chemotherapy and checkpoint inhibitors targeting the PD-1/PD-L1 pathway. Results from the study are being presented as part of a mini-oral presentation at the International Association for the Study of Lung Cancer's (IASLC's) World Conference on Lung Cancer (WCLC), being held this week in Denver, Colorado.
PPHMP: 22.92 (+0.25), PPHM: 0.36 (unch)
Peregrine to Report Financial Results for First Quarter of Fiscal Year 2016 After Market Close on September 9, 2015
GlobeNewswire - Thu Sep 03, 3:05PM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQPHM) (NASDAQPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that it will report financial results for the first quarter of fiscal year 2016 ended July 31, 2015 on September 9, 2015 after market and will host a conference call and webcast at 1:30 PM Pacific Daylight Time (4:30 PM Eastern Daylight Time). Peregrine's senior management will discuss financial results for the first quarter and review the recent progress of its clinical development programs.
PPHMP: 22.92 (+0.25), PPHM: 0.36 (unch)
AstraZeneca and Peregrine Pharmaceuticals to Collaborate on Immuno-Oncology Combination Clinical Trial
GlobeNewswire - Mon Aug 24, 1:05AM CDT
AstraZeneca (NYSE:AZN) and Peregrine Pharmaceuticals, Inc. (NASDAQPHM) (NASDAQPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that they have entered into a cancer immunotherapy clinical trial collaboration. The collaboration will evaluate Peregrine's investigational phosphatidylserine (PS)-signaling pathway inhibitor, bavituximab, in combination with AstraZeneca's investigational anti-PD-L1 immune checkpoint inhibitor, durvalumab (MEDI4736). The planned Phase I/Ib trial will evaluate the safety and efficacy of bavituximab in combination with durvalumab in multiple solid tumors.
PPHMP: 22.92 (+0.25), AZN: 32.81 (-0.40), PPHM: 0.36 (unch)
Peregrine Pharmaceuticals Reports Fourth Quarter and Year-End Fiscal Year 2015 Financial Results and Recent Developments
GlobeNewswire - Tue Jul 14, 3:05PM CDT
-- Phase III SUNRISE Clinical Trial on Track to Complete Patient Enrollment by Calendar Year-End 2015 -
PPHMP: 22.92 (+0.25), PPHM: 0.36 (unch)
Avid Bioservices to Participate in Cambridge Healthtech Institute's (CHI) 8th Annual The Bioprocessing Summit
GlobeNewswire - Tue Aug 09, 7:05AM CDT
Avid Bioservices, Inc., a wholly owned subsidiary of Peregrine Pharmaceuticals, Inc. (NASDAQ
PHM) (NASDAQPHMP), today announced that the company will have a significant presence at Cambridge Healthtech Institute's (CHI) 8 Annual The Bioprocessing Summit, being held August 15-19, 2016 in Boston, MA. The company's vice president of process sciences, Pete Gagnon, will make a presentation centered on the role of protein A in biomanufacturing and will serve as one of three expert participants for a panel discussion on technology advancements that can assist biological drug manufacturers in achieving optimal viral clearance during the performance of downstream purification processes. PPHMP: 22.92 (+0.25), PPHM: 0.36 (unch)
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
GlobeNewswire - Thu Jun 02, 3:00PM CDT
Peregrine Pharmaceuticals, Inc. (Nasdaq
PHM) (NasdaqPHMP) today announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock". PPHMP: 22.92 (+0.25), PPHM: 0.36 (unch)
Peregrine Pharmaceuticals Provides Corporate Update Highlighting Latest Developments for Contract Manufacturing and Drug Development Businesses
GlobeNewswire - Thu Jun 02, 7:05AM CDT
- Contract Manufacturing Revenue Hits All-Time High of $44 Million for Fiscal Year Ended April 2016; Fiscal Year 2017 Contract Manufacturing Revenue Projected Between $50-55 Million; Continued Growth Expected to Lead to Future Sustainable Profitability in 24 Months -
PPHMP: 22.92 (+0.25), PPHM: 0.36 (unch)
Avid Bioservices to Exhibit at the 2016 BIO International Convention
Marketwired - Tue May 31, 7:05AM CDT
Showcasing Expanded Contract Manufacturing Capabilities From Early Stage Development to Commercialization; Onsite Access to Leading Biopharmaceutical Manufacturing Experts
PPHMP: 22.92 (+0.25), PPHM: 0.36 (unch)
Avid Bioservices Appoints Pete Gagnon as Vice President of Process Sciences
Marketwired - Mon May 23, 7:05AM CDT
Leading Innovator in Field of Biologics Purification Brings Unique Manufacturing Experience to Broaden Avid's Capabilities, Including Biosimilar Expertise
PPHMP: 22.92 (+0.25), PPHM: 0.36 (unch)
Preclinical Data Presented at American Association for Cancer Research (AACR) Annual Meeting Demonstrate Enhanced Therapeutic Benefit of Combining a PS-Targeting Antibody With Anti-PD-1 Therapy in Models of Triple Negative Breast Cancer (TNBC)
GlobeNewswire - Wed Apr 20, 7:05AM CDT
- Statistically Significant Improvement in Overall Survival for Combination as Compared to Anti-PD-1 Therapy Alone in TNBC Models; Combination Also Protects Against Re-Challenge With TNBC Tumor Cells -
PPHMP: 22.92 (+0.25), PPHM: 0.36 (unch)
Peregrine Pharmaceuticals and National Comprehensive Cancer Network (NCCN) Form Clinical Collaboration to Evaluate Novel Cancer Treatment Combinations With Bavituximab
GlobeNewswire - Wed Jan 06, 7:05AM CST
Peregrine Pharmaceuticals, Inc. (NASDAQ
PHM) (NASDAQPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced a new research collaboration with the National Comprehensive Cancer Network(R) (NCCN(R)) to expand the company's ongoing clinical research and development of bavituximab for the treatment of a range of tumors. NCCN, a not-for-profit alliance of 26 of the world's leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Peregrine will fund multiple investigator-initiated clinical and correlative studies with bavituximab in multiple cancers at NCCN Member Institutions and their affiliate community hospitals through a $2 million research grant to NCCN's Oncology Research Program (ORP). NCCN will be responsible for oversight and monitoring of the clinical studies through the research grant. PPHMP: 22.92 (+0.25), PPHM: 0.36 (unch)
Peregrine Pharmaceuticals Reports Financial Results for Second Quarter of Fiscal Year 2016 and Recent Developments
GlobeNewswire - Thu Dec 10, 3:05PM CST
--Peregrine and AstraZeneca Expand Immuno-Oncology Collaboration and Plan Phase II NSCLC Trial--
PPHMP: 22.92 (+0.25), PPHM: 0.36 (unch)
Peregrine Pharmaceuticals' board to pay USD0.65625 per preferred share dividend
M2 - Tue Dec 08, 3:44AM CST
The board of directors of Peregrine Pharmaceuticals (Nasdaq
PHMP) declared on Monday its quarterly dividend of USD0.65625 per share on its 10.50% Series E convertible preferred stock accruing from 1 October 2015 through 31 December 2015. PPHMP: 22.92 (+0.25)
Peregrine to Report Financial Results for Second Quarter of Fiscal Year 2016 After Market Close on December 10, 2015
GlobeNewswire - Thu Dec 03, 3:05PM CST
Peregrine Pharmaceuticals, Inc. (NASDAQ
PHM) (NASDAQPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that it will report financial results for the second quarter of fiscal year 2016 ended October 31, 2015 on December 10, 2015 after market and will host a conference call and webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Peregrine's senior management will discuss financial results for the second quarter and review the recent progress of its clinical development programs. PPHMP: 22.92 (+0.25), PPHM: 0.36 (unch)
Peregrine Pharmaceuticals to Participate in Two Upcoming Life Science Investor Conferences
GlobeNewswire - Mon Nov 23, 7:05AM CST
Peregrine Pharmaceuticals, Inc. (NASDAQ
PHM) (NASDAQPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that the company will participate in two upcoming life science investor conferences being held in New York during the month of December. Steven W. King, president and chief executive officer, will participate in a panel discussion focused on cancer immunotherapy at Piper Jaffray's 27 Annual Healthcare Conference. Additionally, the company will be one of only 16 life science companies attending Roth Capital Partners' Immuno-Oncology Corporate Access Day. PPHMP: 22.92 (+0.25), PPHM: 0.36 (unch)
New Preclinical Data Presented at SITC Annual Meeting Highlight Bavituximab's Enhanced Anti-Tumor Activity When Combined With Checkpoint Inhibitors in Breast Cancer and Melanoma
GlobeNewswire - Mon Nov 09, 7:05AM CST
- Bavituximab in Combination with Anti-PD-1 in Breast Cancer Studies Showed a Statistically Significant Improvement in Overall Survival as Compared to Subjects Receiving Anti-PD-1 Therapy Alone -
PPHMP: 22.92 (+0.25), PPHM: 0.36 (unch)
AstraZeneca and Peregrine Pharmaceuticals Expand Ongoing Immuno-Oncology Collaboration to Include Phase II Lung Cancer Combination Clinical Trial
GlobeNewswire - Thu Oct 15, 7:05AM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ
PHM) (NASDAQPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that it has expanded its ongoing cancer immunotherapy clinical collaboration with AstraZeneca to include a second, later-stage trial. The companies will now also evaluate the immunotherapy combination of Peregrine's phosphatidylserine (PS)-targeted immune-activator, bavituximab, and AstraZeneca's anti-PD-L1 immune checkpoint inhibitor, durvalumab (MEDI4736), in a global Phase II study in patients with previously treated squamous or non-squamous non-small cell lung cancer (NSCLC). The randomized Phase II trial will be conducted by Peregrine. PPHMP: 22.92 (+0.25), PPHM: 0.36 (unch)
New Translational Data Highlights Bavituximab's Ability to Induce Signs of Immune Activation in Lung Cancer Tumor Samples With Negative PD-L1 Expression
GlobeNewswire - Tue Sep 08, 7:08AM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ
PHM) (NASDAQPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced positive new data from a translational study of bavituximab, the company's investigational phosphatidylserine (PS)-signaling pathway inhibitor. Findings demonstrated the ability of bavituximab, alone or in combination with docetaxel, to induce signs of immune activation in non-small cell lung cancer (NSCLC) patient-derived tumor samples, particularly when there was negative PD-L1 expression in the tumor sample. These data further support the potential mechanistic synergies for bavituximab with chemotherapy and checkpoint inhibitors targeting the PD-1/PD-L1 pathway. Results from the study are being presented as part of a mini-oral presentation at the International Association for the Study of Lung Cancer's (IASLC's) World Conference on Lung Cancer (WCLC), being held this week in Denver, Colorado. PPHMP: 22.92 (+0.25), PPHM: 0.36 (unch)
Peregrine to Report Financial Results for First Quarter of Fiscal Year 2016 After Market Close on September 9, 2015
GlobeNewswire - Thu Sep 03, 3:05PM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ
PHM) (NASDAQPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that it will report financial results for the first quarter of fiscal year 2016 ended July 31, 2015 on September 9, 2015 after market and will host a conference call and webcast at 1:30 PM Pacific Daylight Time (4:30 PM Eastern Daylight Time). Peregrine's senior management will discuss financial results for the first quarter and review the recent progress of its clinical development programs. PPHMP: 22.92 (+0.25), PPHM: 0.36 (unch)
AstraZeneca and Peregrine Pharmaceuticals to Collaborate on Immuno-Oncology Combination Clinical Trial
GlobeNewswire - Mon Aug 24, 1:05AM CDT
AstraZeneca (NYSE:AZN) and Peregrine Pharmaceuticals, Inc. (NASDAQ
PHM) (NASDAQPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that they have entered into a cancer immunotherapy clinical trial collaboration. The collaboration will evaluate Peregrine's investigational phosphatidylserine (PS)-signaling pathway inhibitor, bavituximab, in combination with AstraZeneca's investigational anti-PD-L1 immune checkpoint inhibitor, durvalumab (MEDI4736). The planned Phase I/Ib trial will evaluate the safety and efficacy of bavituximab in combination with durvalumab in multiple solid tumors. PPHMP: 22.92 (+0.25), AZN: 32.81 (-0.40), PPHM: 0.36 (unch)
Peregrine Pharmaceuticals Reports Fourth Quarter and Year-End Fiscal Year 2015 Financial Results and Recent Developments
GlobeNewswire - Tue Jul 14, 3:05PM CDT
-- Phase III SUNRISE Clinical Trial on Track to Complete Patient Enrollment by Calendar Year-End 2015 -
PPHMP: 22.92 (+0.25), PPHM: 0.36 (unch)
